A Study of Tirzepatide (LY3298176) Versus Placebo in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine With or Without Metformin
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 475 participants.
Also called NCT04039503
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 475 participants
- Sponsor
- Registry
-
NCT04039503 -
2019-000860-99
-
- Other papers using this trial's data
- Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Czechia, Germany, Japan, Poland, Puerto Rico, Slovakia, Spain
- Registry status
- Completed
Technical summary
Registry record NCT04039503. Randomized; double masking; primary purpose treatment. Start 2019-08-30 (actual); primary completion 2020-12-22 (actual). Results posted on 2022-01-12.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study of Tirzepatide (LY3298176) Versus Placebo in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine With or Without Metformin
- Acronym
- SURPASS-5
- Condition
- Type 2 Diabetes
- Intervention (Drug)
- Tirzepatide
- Intervention (Drug)
- Placebo
- Lead sponsor
- Eli Lilly and Company
Record details
- Record id
cardio:ct-nct04039503- Content hash
067ff883f80850e483972a27e10282bd53bb7bb24abe2a2e54f6dc0379b31425